Back to Search Start Over

Safety of freeze‐dried mycelia of Antrodia camphorata as a novel food pursuant to regulation (EU) 2015/2283.

Authors :
Turck, Dominique
Bohn, Torsten
Castenmiller, Jacqueline
De Henauw, Stefaan
Hirsch‐Ernst, Karen Ildico
Maciuk, Alexandre
Mangelsdorf, Inge
McArdle, Harry J
Naska, Androniki
Pelaez, Carmen
Pentieva, Kristina
Siani, Alfonso
Thies, Frank
Tsabouri, Sophia
Vinceti, Marco
Cubadda, Francesco
Frenzel, Thomas
Heinonen, Marina
Marchelli, Rosangela
Neuhäuser‐Berthold, Monika
Source :
EFSA Journal; Jun2022, Vol. 20 Issue 6, p1-16, 16p
Publication Year :
2022

Abstract

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on freeze‐dried mycelia of Antrodia camphorata as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is produced by solid‐state cultivation from tissue cultures derived from the fungus Antrodia camphorata. The applicant intends to market the NF in food supplements at a maximum dose of 990 mg per day. The target population is the general population. The NF mainly consists of carbohydrates, proteins and fats, and it contains numerous constituents, such as β‐glucans, antroquinonol and triterpenoids. Taking into account the composition of the NF and the proposed conditions of use, the consumption of the NF is not nutritionally disadvantageous. There are no concerns regarding genotoxicity of the NF. Based on a 90‐day repeated dose toxicity study and a prenatal developmental toxicity study performed with the NF, the Panel derives a safe level of 16.5 mg/kg body weight per day. The Panel concludes that the NF, freeze‐dried mycelia of Antrodia camphorata, is safe at the proposed use level for individuals aged 14 years and above. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
18314732
Volume :
20
Issue :
6
Database :
Complementary Index
Journal :
EFSA Journal
Publication Type :
Academic Journal
Accession number :
157755859
Full Text :
https://doi.org/10.2903/j.efsa.2022.7380